Patent 9,309,229: Scope, Claims, and Patent Landscape Analysis
What does Patent 9,309,229 cover?
Patent 9,309,229, filed by Gilead Sciences Inc., grants protection for a specific class of antiviral compounds, their synthesis methods, formulations, and therapeutic applications. The patent title is "Novel 2'-C-ethyl substituted nucleoside analogs with antiviral activity." It was granted on April 5, 2016, and expires on April 5, 2033, assuming no extensions or litigations.
Key elements of the patent
- Chemical scope: The patent mainly claims a class of 2'-C-ethyl nucleoside analogs with modifications at the sugar and base moieties.
- Synthesis methods: Methods for preparing these analogs, including specific reaction steps and intermediates.
- Pharmacological applications: Uses in treating hepatitis B virus (HBV) and hepatitis C virus (HCV) infections.
- Formulations: Pharmaceutical compositions containing the claimed compounds for oral administration.
What are the primary claims?
The patent includes 20 claims, with the broadest being:
Claim 1: A 2'-C-ethyl nucleoside analog compound of formula I or its pharmaceutically acceptable salt, characterized by specific substitutions on the nucleoside sugar and base.
Claim 2: A method for synthesizing the compound of claim 1, involving steps such as nucleoside modification and substitution reactions.
Claim 15: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Claim scope analysis
- Broadness: Claim 1 broadly covers any 2'-C-ethyl nucleoside analogs with particular substitution patterns, but excludes other modifications outside the specified scope.
- Specificity: Claims 2-14 detail particular synthetic routes, serving as dependent claims to the broad compound claim.
- Use claims: Claims 15-20 focus on therapeutic applications and formulations, emphasizing treatment of viral infections.
Patent landscape and prior art comparison
Major related patents
- US Patent 9,044,464: Also owned by Gilead; covers nucleotide analogs similar to those in 9,309,229, with overlapping structures but different substitutions.
- WO2014139736: International patent application claiming C-ethenyl nucleoside analogs, published in 2014, predating the 9,309,229 patent.
Overlap with prior art
- Pre-existing nucleoside analog patents: Prior to 2015, numerous patents covered C-alkyl, C-ethenyl, and other substituted nucleosides for antiviral use.
- Novelty and inventive step: Patent 9,309,229 distinguishes itself by specific 2'-C-ethyl substitutions and synthesis pathways not fully covered by pre-existing patents.
Patent family and jurisdiction coverage
- Family members: Several divisional and continuation applications extend the scope to Europe, Japan, and Canada.
- Patent lifecycle: The US patent expires in 2033; similar patents in other jurisdictions are pending or issued.
Litigation and licensing
- No public litigation records directly involving Patent 9,309,229.
- Gilead has licensed the underlying compounds to multiple pharmaceutical entities, supporting commercialization efforts.
Implications for the industry
- The patent secures exclusive rights over specific 2'-C-ethyl nucleoside analogs, laying the groundwork for HBV and HCV therapies.
- The scope influences generic manufacturers from designing around the claims, focusing on different substitutions or configurations.
- The patent landscape demonstrates an active domain with overlapping claims, requiring careful navigation to avoid infringement.
Key technical points
| Aspect |
Details |
| Patent number |
9,309,229 |
| Filing date |
December 23, 2013 |
| Issue date |
April 5, 2016 |
| Expiry date |
April 5, 2033 |
| Inventors |
Zhang et al. |
| Assignee |
Gilead Sciences Inc. |
| Claim scope |
20 claims covering compounds, synthesis methods, and uses |
| Key compound class |
2'-C-ethyl nucleoside analogs |
Summary
Patent 9,309,229 covers a class of 2'-C-ethyl nucleoside analogs with specific substitution patterns, their synthesis, and therapeutic uses against hepatitis viruses. Its claims are broad but specify the chemical structure and synthesis methods, with patent family extensions in multiple jurisdictions. The patent sits within an active landscape of nucleoside analog patents, with prior art establishing foundational coverage in this area. Its expiration in 2033 provides a timeframe for potential generic entry, subject to licensing or design-around strategies.
Key Takeaways
- The patent's broad compound claims protect a specific subset of nucleoside analogs active against hepatitis viruses.
- The scope overlaps with previous nucleoside compound patents but introduces novel substitutions and synthesis steps.
- Its geographic coverage and patent family extensions extend protection beyond the US.
- The patent’s expiration in 2033 marks a significant period for generic competition and biosimilar development.
- Companies designing nucleoside analog therapeutics must carefully evaluate claim overlap, synthesis methods, and jurisdictional rights.
FAQs
Q1: How does Patent 9,309,229 differ from prior nucleoside analog patents?
A: It claims specific 2'-C-ethyl substitutions with unique synthesis methods not disclosed in earlier patents.
Q2: When does Patent 9,309,229 expire?
A: April 5, 2033, assuming no extensions.
Q3: Are there licensing opportunities associated with this patent?
A: Gilead has licensed related compounds, but specific licensing terms for Patent 9,309,229 are typically confidential.
Q4: Can generics develop similar compounds without infringement?
A: They can explore different substitutions outside the scope of claims or alternative synthesis routes.
Q5: How active is the patent landscape around nucleoside antiviral analogs?
A: Highly active, with overlapping patents in multiple jurisdictions and ongoing innovation.
References
[1] U.S. Patent No. 9,309,229. (2016). Gilead Sciences Inc.
[2] Gilead Sciences Inc. (2014). US Patent Application 2014/0229924.
[3] World Intellectual Property Organization. (2014). WO2014139736.
[4] Li, T., et al. (2016). "Advances in nucleoside analogs for hepatitis virus treatment." Antiviral Research, 131, 179-192.
